Vertex Gains In Vivo CRISPR Foothold With Mammoth Pact
Executive Summary
Deal Snapshot: The nearly $700m deal gives Vertex, already with a major foothold in CRISPR, access to Mammoth’s ultra-compact gene-editing technology in two diseases.
You may also be interested in...
Vertex Expands In Vivo Gene-Editing Plans With Verve Liver Disease Pact
Vertex is expanding its investments across advanced therapies again, R&D chief David Altshuler adding a second in vivo gene-editing deal to its pipeline.
Bayer Consolidates Next-Generation Gene Editing Focus With Mammoth Deal
The German major will collaborate with the US biotech to develop CRISPR gene-editing therapies, solidifying its interest in next-generation therapeutics.
Gene-Editing Companies To Watch At J.P. Morgan
Share prices for many gene-editing companies declined in 2021, but the field is burgeoning with novel approaches due to be highlighted at the J.P. Morgan meeting, and one player, Intellia, could move closer to a breakthrough in 2022.